Defensive Taktiken

A poison pill allows shareholders to purchase additional stock at a discount, diluting the acquirer's stake and making the company more expensive to acquire. This strategy deters hostile bidders by increasing the financial burden of takeover attempts. For example, Airgas used this tactic in 2010 to block Air Products' hostile bid.

Shark repellent involves procedural changes to corporate bylaws, such as requiring a supermajority vote for mergers. These governance modifications create barriers that make takeovers harder to execute, complementing other defensive tactics by focusing on structural obstacles rather than shareholder actions.

A golden parachute provides lucrative compensation packages to executives if a takeover occurs, including severance pay, bonuses, or stock options. This increases the financial burden on acquirers, deterring bids. However, it can raise concerns about prioritizing executive interests over shareholder value.

A white knight is a friendly acquirer who purchases the company on favorable terms, protecting it from hostile bidders. Unlike other tactics that deter takeovers, this strategy allows the company to retain influence over its future while accepting acquisition on acceptable conditions.

Defensive tactics can spark debates about their impact on shareholder rights and long-term value creation. While protecting corporate independence, these strategies may prioritize management interests over shareholders and can complicate financial side effects of acquisition, requiring careful navigation of stakeholder dynamics.

Defensive tactics help companies resist unwanted takeovers and protect their autonomy by deterring hostile bidders or improving acquisition terms. These strategies enable companies to maintain control over their direction and negotiate more favorable conditions during potential acquisitions and protect shareholder interests.

While defensive tactics can delay or complicate takeovers, they may not always prevent them entirely. For instance, Twitter adopted a poison pill in 2022 to counter Elon Musk's acquisition attempt, but ultimately agreed to the deal, demonstrating that such measures have limitations.